Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: A case report

Blood

Volumn 98, Issue 9, 2001, Pages 2865-2868

  Piekarz, Richard L ^a,b   Robey, Rob ^a   Sandor, Victor ^b   Bakke, Susan ^b   Wilson, Wyndham H ^a   Dahmoush, Laila ^a   Kingma, Douglas M ^b   Turner, Maria L ^b   Altemus, Rosemary ^b   Bates, Susan E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEPSIPEPTIDE; FR 901228; HISTONE DEACETYLASE INHIBITOR;

ADULT; AGED; ARTICLE; CASE REPORT; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DEACETYLATION; DRUG EFFICACY; HUMAN; HUMAN CELL; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEZARY CELL; SKIN LYMPHOMA; T CELL LYMPHOMA;

EID: 0035525781     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.9.2865     Document Type: Article

References (19)

1. Chan WC, Armitage JO, Gascoyne R, et al. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood. 1997;89:3909-3918.
2. Campo E, Gaulard P, Zucca E, et al. Report of the European task force on lymphomas: workshop on peripheral T-cell lymphomas. Ann Oncol. 1998;9:835-843.
3. Siegel RS, Pandolfino T, Guitart J, Rosen S, Kuzel TM. Primary cutaneous T-cell lymphoma: review and current concepts. J Clin Oncol. 2000;18:2908-2925.
4. Willemze R, Kerl H, Sterry W, et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood. 1997;90:354-371.
5. Bunn PA Jr, Hoffman SJ, Norris D, Golitz LE, Aeling JL. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sezary syndrome). Ann Intern Med. 1994;121:592-602.
6. Ueda H, Nakajima H, Hori Y, et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968, I: Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J Antibiot (Tokyo). 1994;47:301-310.
7. Ueda H, Manda T, Matsumoto S, et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968, III: antitumor activities on experimental tumors in mice. J Antibiot (Tokyo). 1994;47:315-323.
8. Lee JS, Paull K, Alvarez M, et al. Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol Pharmacol. 1994;46:627-638.
9. Nakajima H, Kim YB, Terano H, Yoshida M, Horinouchi S. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res. 1998;241:126-133.
10. Cress WD, Seto E. Histone deacetylases, transcriptional control, and cancer. J Cell Physiol. 2000;184:1-16.
11. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer-treatment. Cancer. 1981;47:207-214.
12. Zinzani PL, Baliva G, Magagnoli M, et al. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol. 2000;18:2603-2606.
13. Ueda H, Nakajima H, Hori Y, Goto T, Okuhara M. Action of FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968, on Ha-ras transformed NIH3T3 cells. Biosci Biotechnol Biochem. 1994;58:1579-1583.
14. Sander V, Senderowicz A, Mertins S, et al. P21-dependent G(1) arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br J Cancer. 2000;83:817-825.
15. Wang R, Brunner T, Zhang L, Shi Y. Fungal metabolite FR901228 inhibits c-Myc and Fas ligand expression. Oncogene. 1998;17:1503-1508.
16. Koyama Y, Adachi M, Sekiya M, Takekawa M, Imai K. Histone deacetylase inhibitors suppress IL-2-mediated gene expression prior to induction of apoptosis. Blood. 2000;96:1490-1495.
17. Wang J, Hoshino T, Redner RL, Kajigaya S, Liu JM. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc Natl Acad Sci U S A. 1998;95:10860-10865.
18. Redner RL, Wang JX, Liu JM. Chromatin remodeling and leukemia: new therapeutic paradigms. Blood. 1999;94:417-428.
19. Shao RH, Urbano AG, Foss FM. Modulation of DAB3891L-2 (ONTAC) cytotoxicity in leukemia and lymphoma by arginine butyrate and all-trans retinoic acid. Proc Am Soc Clin Oncol. 2000;19:19a.